Values | |
---|---|
ASPs during SARS-CoV-2 pandemic, n (%) | |
Unchanged | 2 (11.1) |
Reduced | 9 (50) |
Suspended | 7 (38.9) |
ASPs post SARS-CoV-2 pandemic, n (%) | |
Back to pre-pandemic activity | 7 (38.9) |
Ongoing but are still reduced | 7 (38.9) |
Remain suspended | 4 (22.2) |
Monitoring of high-cost antibiotic prescription, n (%) | 6 (33.3) |
Regular reports on antimicrobial usage, n (%) | 6 (33.3) |
Regular reports on the epidemiology of microbial isolates, n (%) | 9 (50) |
Ordinary wards converted into COVID-19 wards, n (%) | 18 (100) |
Number of beds dedicated to COVID-19 patients (April 2020) | |
50 | 3 (16.7) |
50–100 | 10 (55.6) |
100–250 | 5 (27.8) |
250–500 | 0 |
> 500 | 0 |
Number of beds dedicated to COVID-19 patients (August 2020) | |
50 | 16 (88.9) |
50–100 | 1 (5.6) |
100–250 | 1 (5.6) |
250–500 | 0 |
> 500 | 0 |
AMS team members shifted to clinical activity in COVID-19 wards, n (%) | 13 (100) a |
MDRO hospital acquired infections outbreaks in COVID-19 wards during the pandemic, n (%) | 16 (88.9) |
Carbapenem-resistant Enterobacterales (CRE) | 8 (44.4) |
Vancomycin-resistant enterococci (VRE) | 11 (61.1) |
MDR A. baumanni | 11 (61.1) |
MDR P. aeruginosa | 11 (61.1) |
Candida auris | 0 |